Search results
Results from the WOW.Com Content Network
[42] c-KIT- and PDGFRA-mutation negative GIST tumors are usually resistant to treatment with imatinib, [16] as is neurofibromatosis-1-associated wild-type GIST. [37] A specific subtype of PDGFRA mutation, D842V, is also insensitive to imatinib. [37] [43] Recently, in PDGFRA-mutated GIST, avapritinib has been approved by FDA. [44]
Conventional CT and MRI should be performed with cuts of 10 mm or less in slice thickness contiguously. Spiral CT should be performed using a 5 mm contiguous reconstruction algorithm. This applies to tumors of the chest, abdomen and pelvis. Head and neck tumors and those of extremities usually require specific protocols.
The prognosis for these types of tumors depends heavily on the size of the tumor and the rate of mitosis, however approximately 60 percent of GISTs are diagnosed as benign. [4] Surgery to remove the tumor is the primary treatment method, although imatinib, everolimus, and rapamycin may soon be approved as alternative treatment and management ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
Surgery is the most common form of the treatment for most sarcomas that have not spread to other parts of the body, and for most sarcomas, surgery is the only curative treatment. [ 3 ] [ 19 ] Limb-sparing surgery , as opposed to amputation, can now be used to save the limbs of patients in at least 90% of extremity (arm or leg) sarcoma cases. [ 19 ]
The treatment depends on the location of the tumor, as well as the type of cancer cell and whether it has invaded other tissues or spread elsewhere. These factors also determine the prognosis. Overall, the GI tract and the accessory organs of digestion (pancreas, liver, gall bladder) are responsible for more cancers and more deaths from cancer ...
The WHO Classification of Tumours, more commonly known as the WHO Blue Books, is a series of books that classify tumours.They are compiled by expert consensus and published by the World Health Organization's (WHO) International Agency for Research on Cancer (IARC).
M8591/1 Sex cord-gonadal stromal tumor, incompletely differentiated M8592/1 Sex cord-gonadal stromal tumor, mixed forms M8593/1 Stromal tumor with minor sex cord elements M8600/0 Thecoma, NOS Theca cell tumor; M8600/3 Thecoma, malignant M8601/0 Thecoma, luteinized M8602/0 Sclerosing stromal tumor M8610/0 Luteoma, NOS Luteinoma